Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Exelixis, Inc. (EXEL) vs Summit Therapeutics PLC (SMMT)

Exelixis, Inc. and Summit Therapeutics PLC are both Biotechnology companies. Exelixis, Inc. and Summit Therapeutics PLC are of similar size ($14.4B and $13.1B). Summit Therapeutics PLC has negative trailing earnings, so its P/E is not meaningful; Exelixis, Inc. trades at 17.6×. Exelixis, Inc. grew revenue faster over the last twelve months: 9.23% against −61.0%. Exelixis, Inc. has the higher net margin (35.3% vs 0.00%) and the higher return on invested capital (60.5% vs 0.00%). Across the 18 metrics below, Exelixis, Inc. leads on 16 and Summit Therapeutics PLC on 2.

Valuation

Metric EXEL SMMT Biotechnology median
P/E 17.60 n/m 7.88
P/S 5.98 17,230.45 11.47
P/B 7.90 19.28 2.52
Price to free cash flow 12.58 n/m 21.16
EV/EBITDA 13.92 n/m 0.74
EV/Sales 5.71 16,392.16 10.73
Earnings yield 5.68% (7.17%) (28.84%)
Free cash flow yield 7.95% (3.79%) (23.03%)

Profitability

Metric EXEL SMMT Biotechnology median
Gross margin 96.48% 100.00% 65.16%
Operating margin 39.88% 0.00% 0.00%
Net margin 35.33% 0.00% 0.00%
Free cash flow margin 47.55% 0.00% 0.00%
Return on equity 44.39% (192.50%) (57.72%)
Return on assets 33.28% (159.09%) (49.22%)
Return on invested capital 60.45% 0.00% 0.00%

Growth

Metric EXEL SMMT Biotechnology median
Revenue growth (TTM) 9.23% (61.03%) 5.64%
EPS growth (last fiscal year) 57.95% (364.52%) —
Revenue growth, 5-year CAGR 18.63% (46.49%) 8.40%
Net income growth, 5-year CAGR 47.58% 0.00% 0.00%

Health

Metric EXEL SMMT Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 3.46 6.96 4.73
Net debt to EBITDA (1.18) 0.65 0.96

Dividend

Metric EXEL SMMT Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric EXEL SMMT Biotechnology median
Market cap 14.40b 13.12b 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack